"Pharmaxis continues to interact with more than a dozen larger companies as our NASH development program progresses and we expect that our LOXL2 small molecule inhibitor program will generate a competitive partnering process after completing phase 1 clinical trials, currently scheduled to commence in the second half of 2017"
I think the last time the CEO was this descriptive about progress was the months leading up to the Boehringer Ingelheim deal.
GLTA
PXS Price at posting:
27.0¢ Sentiment: Buy Disclosure: Held
